NICE gives initial no for Novartis's Glivec for post surgery GIST
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, is not minded to recommend Novartis's Glivec (imatinib) as an adjuvant treatment for gastrointestinal stromal tumours (GIST) for use on the NHS, it says in preliminary draft guidance published yesterday.